| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.05 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.05 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.073 | 0.05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.094 | 0.05 |